Economist Argues Maximizing Shareholder Value Hurts Drug Innovation

Episode Summary

Executive Summary: Economist William Lazonick argues that U.S. pharma’s “financialized” model prioritizes shareholder payouts, stock buybacks, and executive compensation over innovation and affordable medicines. He says high drug prices are used to prop up stock prices rather than fund R&D, and calls for banning buybacks, reforming pay, changing boards, and regulating prices for drugs built on public investment.

Main Topics: Pharma financialization and shareholder value (Priority: 5/5): Lazonick argues large drug companies have shifted from innovation to maximizing stock prices and shareholder payouts, especially through buybacks and dividends. Drug prices and innovation (Priority: 5/5): The conversation centers on his claim that high prices do not necessarily produce more innovation; instead they often subsidize financial engineering and executive enrichment. Stock buybacks and executive compensation (Priority: 5/5): He says buybacks manipulate share prices and that executive pay is overwhelmingly stock-based, creating incentives to prioritize short-term market performance over drug development. Role of public funding in drug development (Priority: 4/5): Lazonick emphasizes that taxpayers and public institutions such as NIH materially support drug discovery, so companies should not frame innovation as purely privately financed. Corporate governance reform (Priority: 4/5): He proposes changing boards to include workers and taxpayer representation so corporate decisions better reflect public and long-term innovation interests. Policy response to high drug prices (Priority: 4/5): The interview outlines policy remedies including banning buybacks, restructuring compensation, and regulating prices for drugs developed with public subsidies or protection.

Key Arguments: High drug prices are not justified when profits are used for buybacks and dividends rather than reinvestment in R&D. Pharmaceutical firms often show substantial R&D spending, but Lazonick argues much of it is not productive or innovation-oriented. Share buybacks are designed to boost stock prices, enriching executives whose compensation is heavily equity-based. Companies like Merck and Pfizer have increasingly become acquisition-and-commercialization machines rather than original innovators. Public funding, especially NIH support, is a major input into drug development, so the public should receive a fair return through pricing and governance. Boards should represent workers and taxpayers, not just shareholders, because employees and the public bear key risks and provide essential support. Regulating prices for publicly supported drugs would not eliminate profits; it would align them with social need and broader access. The current U.S. shareholder-value model contributes to broader economic harms, including inequality and weakened middle-class prosperity.

Data Points: Companies examined: 18 - Drug companies in the S&P 500 index as of January 2016 were analyzed over a 10-year period. Time period studied: 10 years - The working paper examined corporate behavior across a decade. Executive compensation share tied to stock: 80% to 90% - Lazonick says top executives’ compensation is largely stock-based, especially at higher pay levels. NIH funding since 1988 in current dollars: about $1 trillion - He argues public funding has heavily supported pharmaceutical innovation over time. NIH annual funding: about $32 billion per year - He cites current NIH funding as a major contributor to drug development. Gilead CEO pay: over $400 million - Lazonick cites the top executive’s take-home pay in 2014–2015 during blockbuster-drug profits. Gilead buybacks: about $15 billion - He points to massive repurchases during the same period as evidence of financialization. Orphan Drug Act: 1983 - He notes policy subsidies and protections that helped shape biotech and drug development incentives. Broad biotech/financialization era: mid-1980s onward - He identifies the rise of buybacks and shareholder-value ideology as starting in the mid-1980s.

Pivotal Quotes: "“They’re using high profits to pop up their stock prices.”" — William Lazonick: Explaining how major pharmaceutical firms allocate profits instead of reinvesting them in innovation. "“Stock buybacks… have no purpose whatsoever except to manipulate the company’s stock prices.”" — William Lazonick: His strongest statement in support of banning repurchases. "“The whole myth of the shareholders as an investor in the United States is just nonsense.”" — William Lazonick: Arguing that shareholders are not the true investors in innovation-driven industries.

Implications: If Lazonick’s view is correct, pharma reform should target buybacks, equity pay, board composition, and drug pricing—not just R&D levels. The broader message is that innovation policy and access to medicines depend on governing firms for public benefit, not shareholder enrichment.